Results 11 to 20 of about 242,580 (385)

Amyotrophic lateral sclerosis [PDF]

Nature Reviews Disease Primers, 2022
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is characterized by the degeneration of both upper and lower motor neurons, which leads to muscle weakness and eventual paralysis. Until recently, ALS was classified primarily within the neuromuscular domain, although new imaging and neuropathological data have indicated the ...
E. Feldman, Stephen A. Goutman, S. Petri, L. Mazzini, M. G. Savelieff, P. Shaw, G. Sobue   +6 more
semanticscholar   +11 more sources

Amyotrophic Lateral Sclerosis [PDF]

, 2019
The word amyotrophic is derived from Greek, and means “without nourishment to muscles”, lateral means to the sides and sclerosis means hardened (“What is ALS?,” n.d.).
Georgetson, Anastasia M.
core   +4 more sources

Amyotrophic Lateral Sclerosis. [PDF]

The Lancet, 2017
Amyotrophic lateral sclerosis is characterised by the progressive loss of motor neurons in the brain and spinal cord. This neurodegenerative syndrome shares pathobiological features with frontotemporal dementia and, indeed, many patients show features of both diseases. Many different genes and pathophysiological processes contribute to the disease, and
Robert H. Brown, A. Al-Chalabi
semanticscholar   +13 more sources

Amyotrophic lateral sclerosis [PDF]

The Lancet, 2011
Amyotrophic lateral sclerosis (ALS) is an idiopathic, fatal neurodegenerative disease of the human motor system. In this Seminar, we summarise current concepts about the origin of the disease, what predisposes patients to develop the disorder, and discuss why all cases of ALS are not the same.
Kiernan, M, Vucic, S, Cheah, B, Turner, M, Eisen, A, Hardiman, O, Burrell, JR, Zoing, M   +7 more
  +8 more sources

G-CSF Prevents the Progression of Structural Disintegration of White Matter Tracts in Amyotrophic Lateral Sclerosis: A Pilot Trial [PDF]

, 2011
Background: The hematopoietic protein Granulocyte-colony stimulating factor (G-CSF) has neuroprotective and regenerative properties. The G-CSF receptor is expressed by motoneurons, and G-CSF protects cultured motoneuronal cells from apoptosis.
A Nitkunan, A Schneider, AA Gouw, AA Gouw, Agnes Floel, Armin Schneider, B Nefussy, BR Brooks, BR Brooks, BR Stanton, C Pitzer, C Tarella, Christoph Kleinschnitz, D Le Bihan, DM Mezzapesa, E Canu, F Agosta, F Agosta, F Schiavone, G Alon, G Fein, Hagen Schiffbauer, Harald Kugel, J Grosskreutz, J Minnerup, J Phukan, J Senda, JD Mitchell, JS Henkel, Katja Kolpatzik, M Deppe, M Filippi, M Mascalchi, M O'Sullivan, M Sach, M Swash, M Tanaka, MC Ng, MD Lezak, Michael Deppe, MJ Muller, MM van der Graaff, MR Turner, MT Giordana, N Cashman, NK Iwata, R Dengler, R Yamasaki, RA Charlton, RA Charlton, RG Miller, S Abrahams, S Zoccolella, SH Kim, Siawoosh Mohammadi, SM Smith, Stefan Knecht, T Duning, T Pyra, Thomas Duning, Tobias Warnecke, V Kavcic, Wolf Rüdiger Schäbitz, WR Schabitz, Y Zhang   +64 more
core   +11 more sources

Lower and upper motor neuron involvement and their impact on disease prognosis in amyotrophic lateral sclerosis

Neural Regeneration Research, 2022
Amyotrophic lateral sclerosis is a fatal neurodegenerative disease characterized by progressive muscle wasting, breathing and swallowing difficulties resulting in patient’s death in two to five years after disease onset. In amyotrophic lateral sclerosis,
Maria N Zakharova, Anna A Abramova
doaj   +1 more source

Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

Nature Genetics, 2021
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with a lifetime risk of one in 350 people and an unmet need for disease-modifying therapies.
W. V. Rheenen, Rick A. A. van der Spek, Mark K. Bakker, J. Vugt, P. Hop, R. Zwamborn, N. D. Klein, H. Westra, O. Bakker, Patrick Deelen, Gemma L Shireby, E. Hannon, M. Moisse, D. Baird, Restuadi Restuadi, E. Dolzhenko, Annelot M. Dekker, Klara Gawor, H. Westeneng, Gijs H. P. Tazelaar, K. van Eijk, M. Kooyman, Ross P. Byrne, Mark A. Doherty, M. Heverin, A. A. Khleifat, Alfredo Iacoangeli, A. Shatunov, N. Ticozzi, Johnathan Cooper-Knock, Bradley N. Smith, M. Gromicho, S. Chandran, S. Pal, K. Morrison, P. Shaw, J. Hardy, R. Orrell, M. Sendtner, Thomas Meyer, Nazlı A Başak, A. J. van der Kooi, A. Ratti, I. Fogh, C. Gellera, Giuseppe Lauria Pinter, S. Corti, Cristina Cereda, D. Sproviero, S. D'alfonso, G. Soraru', G. Siciliano, M. Filosto, A. Padovani, A. Chiò, A. Calvo, C. Moglia, M. Brunetti, A. Canosa, M. Grassano, E. Beghi, E. Pupillo, G. Logroscino, B. Nefussy, Alma Osmanovic, Angelica Nordin, Y. Lerner, Michal Zabari, M. Gotkine, R. Baloh, S. Bell, P. Vourc'h, P. Corcia, P. Couratier, S. Millecamps, V. Meininger, F. Salachas, J. M. Pardina, A. Assialioui, R. Rojas‐García, P. Dion, J. Ross, A. Ludolph, Jochen H Weishaupt, David Brenner, A. Freischmidt, G. Bensimon, A. Brice, A. Dürr, C. Payan, Safa Saker-Delye, N. Wood, S. Topp, R. Rademakers, L. Tittmann, W. Lieb, A. Franke, S. Ripke, A. Braun, J. Kraft, D. Whiteman, C. Olsen, A. Uitterlinden, A. Hofman, M. Rietschel, S. Cichon, M. Nöthen, P. Amouyel, B. Traynor, A. Singleton, Miguel Mitne Neto, Ruben J. Cauchi, R. Ophoff, M. Wiedau-Pazos, C. lomen-Hoerth, V. V. Van Deerlin, J. Grosskreutz, A. Rödiger, N. Gaur, Alexander Jörk, Tabea Barthel, Erik Theele, B. Ilse, B. Stubendorff, O. Witte, R. Steinbach, C. Hübner, C. Graff, L. Brylev, V. Fominykh, V. Demeshonok, A. Ataulina, B. Rogelj, B. Koritnik, J. Zidar, M. Ravnik-Glavač, D. Glavač, Z. Stevic, V. Drory, M. Povedano, I. Blair, M. Kiernan, Beben Benyamin, R. Henderson, S. Furlong, S. Mathers, P. Mccombe, M. Needham, S. Ngo, G. Nicholson, R. Pamphlett, D. Rowe, F. Steyn, K. Williams, K. Mather, P. Sachdev, A. Henders, L. Wallace, M. Carvalho, S. Pinto, S. Petri, Markus Weber, G. Rouleau, V. Silani, C. Curtis, G. Breen, J. Glass, Robert H. Brown, J. Landers, C. Shaw, P. Andersen, E. Groen, M. A. Es, R. Pasterkamp, Dongsheng Fan, F. Garton, A. McRae, G. Davey Smith, T. Gaunt, M. Eberle, J. Mill, R. Mclaughlin, O. Hardiman, K. Kenna, N. Wray, E. Tsai, H. Runz, L. Franke, A. Al-Chalabi, P. Damme, L. H. van den Berg, J. Veldink   +191 more
semanticscholar   +1 more source

Early Referral to an ALS Center Reduces Several Months the Diagnostic Delay: A Multicenter-Based Study

Frontiers in Neurology, 2020
Objective: To analyze those factors contributing to the diagnostic delay in ALS.Methods: Consecutive ALS patients were categorized as those studied in departmental hospitals and those studied in a referral ALS center.
Marina Martínez-Molina, Marina Martínez-Molina, Herminia Argente-Escrig, Herminia Argente-Escrig, Margarita F. Polo, David Hervás, Marina Frasquet, Marina Frasquet, Victoria Cortés, Teresa Sevilla, Teresa Sevilla, Teresa Sevilla, Teresa Sevilla, Juan F. Vázquez-Costa, Juan F. Vázquez-Costa, Juan F. Vázquez-Costa, Juan F. Vázquez-Costa   +16 more
doaj   +1 more source

Botulinum toxin for the treatment of lower limb cramp pain in patients with Amyotrophic Lateral Sclerosis [PDF]

, 2020
Background: Muscle cramps and pain associated with them can be seen in patients with amyotrophic lateral sclerosis (ALS) and are known to reduce the quality of life. Pharmacological treatment may not benefit all patients in treating these cramps.
Govindarajan, Raghav, Mehta, Tejas, Sommers, Richard   +2 more
core   +2 more sources

Destination Amyotrophic Lateral Sclerosis [PDF]

Frontiers in Neurology, 2021
Amyotrophic Lateral Sclerosis (ALS) is a prototypical neurodegenerative disease characterized by progressive degeneration of motor neurons both in the brain and spinal cord. The constantly evolving nature of ALS represents a fundamental dimension of individual differences that underlie this disorder, yet it involves multiple levels of functional ...
Keon, M, Musrie, B, Dinger, M, Brennan, SE, Santos, J, Saksena, NK   +5 more
openaire   +4 more sources